Elicio Therapeutics ELTX
NASDAQ ELTX
$1.63 +0.02 (+1.24%)
At close: Nov 11, 2026 · 4:00 PM EST

Elicio Therapeutics (ELTX) Restructuring Costs (2022)

Updated

Elicio Therapeutics' Restructuring Costs came in at $3.15 million for Q4 2022, up 12.5% from the prior quarter.

Analysis

Elicio Therapeutics (ELTX) Restructuring Costs (2022) Analysis & Trends

For FY2022, Elicio Therapeutics' Restructuring Costs was $9.19 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Elicio Therapeutics 45.57 Mn -42.34 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 3.15 Mn
Sep 30, 2022 2.80 Mn
API Access

Elicio Therapeutics Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=ELTX&period=max&api_key=YOUR_API_KEY